Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?

Blood reviews - 1 Nov 2011

Falini Brunangelo, Gionfriddo Ilaria, Cecchetti Federica, Ballanti Stelvio, Pettirossi Valentina, Martelli Maria Paola

Abstract excerpt

Acute myeloid leukemia (AML) carrying nucleophosmin (NPM1) mutations displays distinct molecular and clinical-pathological features that led to its inclusion as provisional entity in 2008 WHO classification of myeloid neoplasms. Since NPM1 mutations behave as a founder genetic lesion in AML, they could be an attractive target for therapeutic intervention. Here, we discuss the potential for developing targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NPM1 gene

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Protein Transport

Source

Identifiers

PMID: 21724308
DOI: 10.1016/j.blre.2011.06.001

Genes

NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?PMID 21724308Read ↗

NPM1-mutated acute myeloid leukemia: from bench to bedside.Semantic proximity Read ↗

Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives.Semantic proximity Read ↗

Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.Semantic proximity Read ↗

Nucleophosmin 1: from its pathogenic role to a tantalizing therapeutic target in acute myeloid leukemia.Semantic proximity Read ↗

Nucleophosmin1 (NPM1) abnormality in hematologic malignancies, and therapeutic targeting of mutant NPM1 in acute myeloid leukemiaSemantic proximity Read ↗

Current status and future perspectives in targeted therapy of NPM1-mutated AML.Semantic proximity Read ↗

Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.Semantic proximity Read ↗

Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.Semantic proximity Read ↗

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation.Semantic proximity Read ↗

NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions.Semantic proximity Read ↗

NPM1-Mutated AML: Deciphering the Molecular and Clinical Puzzle in the Era of Novel Treatment StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.